Salmonella choleraesuis as an anticancer agent in a syngeneic model of orthotopic hepatocellular carcinoma

International Journal of Cancer

Volumn 122, Issue 4, 2008, Pages 930-935

  Lee, Che Hsin ^a   Wu, Chao Liang ^a   Shiau, Ai Li ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Cancer therapy; Hepatocellular carcinoma; Orthotopic; Salmonella choleraesuis; Tumor targeted

Indexed keywords

ANGIOGENESIS INHIBITOR; CD4 ANTIGEN; CD8 ANTIGEN; CISPLATIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; PROBIOTIC AGENT; 5(4' HYDROXYBENZYLIDENOIMINO) 3 METHYLISOTHIAZOLO(5,4 D)PYRIMIDINE (7H) 4,6 DIONE; 5(4'-HYDROXYBENZYLIDENOIMINO)-3-METHYLISOTHIAZOLO(5,4-D)PYRIMIDINE-(7H)-4,6-DIONE; ANTINEOPLASTIC AGENT; PYRIMIDINONE DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANAEROBIC BACTERIUM; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; MICROENVIRONMENT; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; SALMONELLA CHOLERAESUIS; SYSTEMIC THERAPY; TREATMENT OUTCOME; TUMOR VOLUME; UPREGULATION; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL LINE; CYTOLOGY; DRUG EFFECT; DRUG SCREENING; IMMUNOLOGY; KIDNEY; LIVER TUMOR; METABOLISM; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; SALMONELLA; SURVIVAL RATE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; HUMANS; INTERFERON TYPE II; KIDNEY; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; PYRIMIDINONES; SALMONELLA; SURVIVAL RATE; THIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 38349025476     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23047     Document Type: Article

References (22)

1. Fox ME, Lemmon MJ, Mauchline ML, Davis TO, Giaccia AJ, Minton NP, Brown JM. Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. Gene Ther 1996;3:173-8.
2. Kimura NT, Taniguchi S, Aoki K, Baba T. Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res 1980;40:2061-8.
3. Pawelek JM, Low KB, Bermudes D. Bacteria as tumour-targeting vectors. Lancet Oncol 2003;4:548-56.
4. Vassaux G, Nitcheu J, Jezzard S, Lemoine NR. Bacterial gene therapy strategies. J Pathol 2006;208:290-8.
5. Ryan RM, Green J, Lewis CE. Use of bacteria in anti-cancer therapies. Bioessays 2006;28:84-94.
6. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA 2001;98:15155-60.
7. Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 1997;57:4537-44.
8. Low KB, Ittensohn M, Le T, Platt J, Sodi S, Amoss M, Ash O, Carmichael E, Chakraborty A, Fischer J, Lin SL, Luo X et al. Lipid A mutant Salmonella with suppressed virulence and TNF-αinduction retain tumor-targeting in vivo. Nat Biotechnol 1999;17:37-41.
9. Zhao M, Yang M, Ma H, Li X, Tan X, Li S, Yang Z, Hoffman RM. Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res 2006;66:7647-52.
10. Zhao M, Yang M, Li XM, Jiang P, Baranov E, Li S, Xu M, Penman S, Hoffman RM. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci USA 2005;102:755-60.
11. Lee CH, Wu CL, Shiau AL. Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models. J Gene Med 2004;6: 1382-93.
12. Lee CH, Wu CL, Shiau AL. Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model. Cancer Gene Ther 2005;12:175-84.
13. Smith HW. The immunization of mice, calves and pigs against Salmonella dublin and Salmonella cholera-esuis infections. J Hyg (Lond) 1965;63:117-35.
14. Hsieh JL, Wu CL, Lee CH, Shiau AL. Hepatitis B virus X protein sensitizes hepatocellular carcinoma cells to cytolysis induced by E1B-deleted adenovirus through the disruption of p53 function. Clin Cancer Res 2003;9:338-45.
15. Lee CH, Wu CL, Tai YS, Shiau AL. Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy. Mol Ther 2005;11:707-16.
16. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH, Tosato G. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995;182:155-62.
17. Mei S, Theys J, Landuyt W, Anne J, Lambin P. Optimization of tumor-targeted gene delivery by engineered attenuated Salmonella typhimurium. Anticancer Res 2002;22:3261-6.
18. Chang CJ, Tai KF, Roffler S, Hwang LH. The immunization site of cytokine-secreting tumor cell vaccines influences the trafficking of tumor-specific T lymphocytes and antitumor efficacy against regional tumors. J Immunol 2004;173:6025-32.
19. Aoki H, Mora O. Upregulation of the IFN-γ-stimulated genes in the development of delayed pigmented spots on the dorsal skin of F1 mice of HR-1 x HR/De. J Invest Dermatol 2005;124:1053-61.
20. Benencia F, Courreges MC, Conejo-Garcia JR, Mohamed-Hadley A, Zhang L, Buckanovich RJ, Carroll R, Fraser N, Coukos G. HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol Ther 2005;12: 789-802.
21. Bannerman DD, Tupper JC, Ricketts WA, Bennett CF, Winn RK, Harlan JM. A constitutive cytoprotective pathway protects endothelial cells from lipopolysaccharide-induced apoptosis. J Biol Chem 2001; 276:14924-32.
22. Jia LJ, Wei DP, Sun QM, Jin GH, Li SF, Huang Y, Hua ZC. Tumor-targeting Salmonella typhimurium improves cyclophosphamide chemotherapy at maximum tolerated dose and low-dose metronomic regimens in a murine melanoma model. Int J Cancer 2007;121:666-74.